Ovarian cancer as a chronic disease: a new treatment paradigm. Highlights of a roundtable discussion.
Spriggs
D R
DR
Developmental Chemotherapy Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
D000971:Antineoplastic Combined Chemotherapy Protocols; D014408:Biomarkers, Tumor / Q000032:analysis; D001952:Bridged-Ring Compounds / Q000008:administration & dosage; D018394:CA-125 Antigen / Q000032:analysis; D002908:Chronic Disease; D004351:Drug Resistance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000628:therapy*; D010166:Palliative Care / Q000379:methods; D010984:Platinum / Q000008:administration & dosage; D012008:Recurrence; D012074:Remission Induction / Q000379:methods; D043823:Taxoids
D014408:Biomarkers, Tumor; D001952:Bridged-Ring Compounds; D018394:CA-125 Antigen; D043823:Taxoids; C080625:taxane; D010984:Platinum